Eli Lilly will present new study results on Foundayo (an oral weight-loss and diabetes drug), Mounjaro, and retatrutide at a major diabetes conference. The Foundayo data showed it worked better than two competing pills for type 2 diabetes.

• •Lilly to present data on Foundayo, Mounjaro, and retatrutide at ADA's 86th Scientific Sessions
• •Foundayo data showed it worked better than two competing pills for type 2 diabetes

Eli Lilly released results from two late-stage trials showing that people who switched from higher-dose Wegovy or Zepbound to lower doses of Lilly's Foundayo pill or lower-dose Zepbound kept nearly all their weight loss over one year. The trials suggest the lower doses work well enough to maintain results when people switch from stronger versions.

• •Two late-stage trials tested switching from higher-dose incretin therapy to lower doses
• •Patients switched to Foundayo pill or lower-dose Zepbound maintained weight loss over one year
• •Results came from Eli Lilly press releases, not yet peer-reviewed

• •A liver failure signal linked to Lilly's Foundayo pushed shares down
• •Analysts say they are not worried about the safety blip

Foundayo, an oral weight-loss pill, is selling slower than Novo Nordisk's Wegovy pill in its first three weeks on the market. Insurance coverage for Foundayo is expected to improve soon, which could help it catch up in sales.

• •Foundayo is trailing Novo's Wegovy pill in its first three weeks on sale
• •Insurance coverage for Foundayo is expected to improve soon

Eli Lilly says its new weight-loss pill Foundayo is off to a good start, but early sales numbers suggest it's not keeping up with Novo Nordisk's oral version. Both companies are competing to sell pill forms of GLP-1 drugs instead of injections.

• •Lilly calls early Foundayo obesity launch 'encouraging'
• •Foundayo sales appear to lag Novo Nordisk's oral GLP-1
• •Both firms competing in pill-form GLP-1 market vs injections